• Price (EUR)188.00
  • Today's Change3.40 / 1.84%
  • Shares traded41.00
  • 1 Year change-7.84%
  • Beta--
Data delayed at least 15 minutes, as of Jun 02 2023 17:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

IQVIA Holdings Inc. is a global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry. The Company operates through three segments: Technology & Analytics Solutions, Research & Development Solutions and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides critical information, technology solutions and real-world insights and services to the Company's life science clients. The Research & Development Solutions segment primarily serves biopharmaceutical customers, providing outsourced clinical research and clinical trial related services. The Contract Sales & Medical Solutions segment provides health care provider, including contract sales and patient engagement services to both biopharmaceutical clients and the broader healthcare market. The Company protects individual patient privacy. The Company conducts business in more than 100 countries.

  • Revenue in USD (TTM)14.49bn
  • Net income in USD1.06bn
  • Incorporated2016
  • Employees87.00k
  • Location
    IQVIA Holdings Inc2400 ELLIS ROADDURHAM 27703United StatesUSA
  • Phone+1 (919) 998-2000
  • Fax+1 (302) 636-5454
  • Websitehttps://ir.iqvia.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
IQV:NYQ since
Pharmaspectra LLCDeal completed14 Aug 202214 Aug 2022Deal completed-17.30%--
Data delayed at least 15 minutes, as of Jun 02 2023 17:44 BST.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.